Physician profile
Adel Ibrahim
NPI 1093709529
$1,602.51
in general payments reported to CMS, 2019-2025
22 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2021: $23.98 · 2022: $236 · 2023: $349 · 2024: $312 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $686.16 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Celgene Corporation | $187.28 | 2023-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $141.50 | 2023 | Farxiga, Breztri |
| Eisai INC. | $91.13 | 2022-2025 | |
| Davol INC. | $59.61 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $52.97 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $44.83 | 2024-2025 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $39.83 | 2025 | Voquezna |
| Gilead Sciences, INC. | $35.14 | 2023-2024 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $34.00 | 2025 | |
| Pharmaessentia USA Corporation | $33.91 | 2024-2025 | Besremi |
| Emd Serono, INC. | $30.40 | 2024-2025 | |
| Pfizer INC. | $25.16 | 2025 | |
| Merck Sharp & Dohme LLC | $19.26 | 2023 | Keytruda |
| Agios Pharmaceuticals, INC. | $19.10 | 2025 | Pyrukynd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $17.51 | 2024 | Empaveli |
| Seagen INC. | $16.12 | 2022 | |
| Celltrion USA INC. | $15.50 | 2023 | Vegzelma |
| Incyte Corporation | $14.92 | 2025 | Jakafi |
| Janssen Pharmaceuticals, INC | $14.20 | 2019 | |
| Alfasigma USA, INC. | $12.67 | 2021 | |
| Organon LLC | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.